Johnson & Johnson (JNJ) 102.46 $JNJ
Point-Of-Care Diagnostic Market by Products, End Users, Over the Counter & Prescription Based - Global Forecast to 2018
M2 - 50 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fvsqk9/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market by Products, End Users, Over the Counter & Prescription Based - Global Forecast to 2018" report to their offering. The global POC diagnostics market has been segmented on the basis of category (infectious diseases testing kits, glucose monitoring kits, cardiac markers, pregnancy and fertility testing kits, and others) and end users (patient professional monitoring kits and patient self-monitoring kits). The glucose monitoring kits market held the largest share - 53.7% - of the global POC diagnostics market in 2013, followed by the infectious diseases testing kits market. Factors such as rising global prevalence of diabetes, technological advancements in self-monitoring of blood glucose, and the growing patient awareness toward POC testing are stimulating the growth of the glucose monitoring kits market. The fastest-growing segment - cardiac-markers market - is projected to grow at a CAGR of 15.3% from 2013 to 2018. This growth is mainly attributed to the increasing number of cardiac patients and the demand of immediate diagnosis of the diseases. Major players such as Roche (Switzerland), Abbott Laboratories, Inc. (U.S.), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), and Alere Inc. (U.S.) are adopting several growth strategies such as new product launches, partnerships, agreements, collaborations, joint ventures, and mergers and acquisition in order to keep pace with the evolving industry trends. The global POC diagnostics market is highly competitive with a large number of global as well as local market players. As of 2012, the global POC diagnostics market excluding the blood glucose monitoring kits market was dominated by Roche (Switzerland), Alere Inc. (U.S.), Siemens AG (Germany), and Beckman Coulter, Inc. (U.S.), which together accounted for -72% of the market. New product launches and partnerships/agreements/collaborations/joint ventures are the major strategies adopted by most market players to achieve growth in the POC diagnostics market. Scope of the Report Product - Infectious Diseases Testing Kits - Glucose Monitoring Kits - Coagulation Monitoring Kits - Urinalysis Testing Kits - Hematology Testing Kits - Cholesterol Test Strips - Drugs of Abuse Testing Kits - Cardiac Markers - Blood Gas/Electrolytes Testing Kits - Tumor/Cancer Markers - Pregnancy and Fertility Testing Kits - Fecal Occult Testing Kits - Food Pathogens Testing Kits - Others Prescription Mode - Over-the-counter (OTC) Testing Kits - Prescription-based Testing Kits End User - Professional Monitoring Kits - Patients Self-Monitoring Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Point-Of-Care Diagnostics Market, By Product 7 Point-Of-Care Diagnostics Market, By Prescription Mode 8 Point-Of-Care Diagnostics Market, By End User 9 Point-Of-Care Diagnostics Market, By Geography 10 Competitive Landscape 11 Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/fv...ointofcare
City of Chicago sues over painkiller marketing
By CARLA K. JOHNSON - AP - Tue Jun 03, 6:35PM CDT
CHICAGO (AP) — The city of Chicago is seeking damages in a lawsuit accusing five drugmakers of deceptively marketing a class of prescription painkiller that can be highly addictive.
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Final Glance: Pharmaceuticals companies
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 03, 12:31PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Jun 03, 12:31PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Medical Devices companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Will China's Price Gouging Accusations Have Any Impact on Johnson & Johnson and Other Eye Care Compa
Rich Duprey, The Motley Fool - Motley Fool - Tue Jun 03, 9:26AM CDT
Source: Wikimedia Commons Yet another industry has run afoul of China's antitrust laws, this time seven companies in eye care that were accused of fixing prices. According to the National Development and Reform Commission, the eye care companies...
Keen Strategy Partners with Effie Worldwide to Share Best Practices on Marketing Effectiveness from the World's Best Marketers
PR Newswire - Tue Jun 03, 5:24AM CDT
Raleigh-based Keen Strategy is partnering with Effie Worldwide to provide strategies on marketing effectiveness from a selection of the most effective marketers in North America.
Jim Cramer's Top Stock Picks: MWV MHR JNJ ADS
at The Street - Tue Jun 03, 5:00AM CDT
Cramer has some advice for Johnson & Johnson and thinks Alliance Data Systems is reviving retail.
Jim Cramer's 'Mad Money' Recap: Individual Stocks Rule
at The Street - Mon Jun 02, 7:16PM CDT
Cramer sounds off against the professional money managers who trade the market like it's merely a basket of commodities.
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
7 Stocks That Will Lift the Dow Jones Industrial Average to New High
at The Street - Mon Jun 02, 11:33AM CDT
Du Pont, Disney, Intel, Johnson & Johnson, Microsoft, Travelers and Exxon Mobil are likely to lift the Dow Jones Industrial Average to a new all-time high in June.
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 11:10AM CDT
Pharmacyclics (PCYC) announced positive late stage data on Imbruvica.
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $102.17
Comtex SmarTrend(R) - Mon Jun 02, 10:42AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.18 today and have reached the first resistance level of $101.82. Analysts will be watching for a cross of the next upside pivot targets of $102.17 and $103.16.
Cosmetic Product Companies Look to Expand Operations - Company Enters Agreement with Major Distributor for Sale of Beauty & Cosmetic Products in North America
PR Newswire - Mon Jun 02, 7:30AM CDT
Consumer goods companies specializing in cosmetics take steps to increase production and value with partnerships and other developments: Verde Media Group Inc. (OTC: VMGI), Elizabeth Arden, Inc. (NASDAQ: RDEN), Avon Products Inc. (NYSE: AVP), The Procter & Gamble Company (NYSE: PG), Johnson & Johnson (NYSE: JNJ) and Colgate-Palmolive Co. (NYSE: CL)
Point-Of-Care Diagnostic Market by Products, End Users, Over the Counter & Prescription Based - Global Forecast to 2018
M2 - 50 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fvsqk9/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market by Products, End Users, Over the Counter & Prescription Based - Global Forecast to 2018" report to their offering. The global POC diagnostics market has been segmented on the basis of category (infectious diseases testing kits, glucose monitoring kits, cardiac markers, pregnancy and fertility testing kits, and others) and end users (patient professional monitoring kits and patient self-monitoring kits). The glucose monitoring kits market held the largest share - 53.7% - of the global POC diagnostics market in 2013, followed by the infectious diseases testing kits market. Factors such as rising global prevalence of diabetes, technological advancements in self-monitoring of blood glucose, and the growing patient awareness toward POC testing are stimulating the growth of the glucose monitoring kits market. The fastest-growing segment - cardiac-markers market - is projected to grow at a CAGR of 15.3% from 2013 to 2018. This growth is mainly attributed to the increasing number of cardiac patients and the demand of immediate diagnosis of the diseases. Major players such as Roche (Switzerland), Abbott Laboratories, Inc. (U.S.), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), and Alere Inc. (U.S.) are adopting several growth strategies such as new product launches, partnerships, agreements, collaborations, joint ventures, and mergers and acquisition in order to keep pace with the evolving industry trends. The global POC diagnostics market is highly competitive with a large number of global as well as local market players. As of 2012, the global POC diagnostics market excluding the blood glucose monitoring kits market was dominated by Roche (Switzerland), Alere Inc. (U.S.), Siemens AG (Germany), and Beckman Coulter, Inc. (U.S.), which together accounted for -72% of the market. New product launches and partnerships/agreements/collaborations/joint ventures are the major strategies adopted by most market players to achieve growth in the POC diagnostics market. Scope of the Report Product - Infectious Diseases Testing Kits - Glucose Monitoring Kits - Coagulation Monitoring Kits - Urinalysis Testing Kits - Hematology Testing Kits - Cholesterol Test Strips - Drugs of Abuse Testing Kits - Cardiac Markers - Blood Gas/Electrolytes Testing Kits - Tumor/Cancer Markers - Pregnancy and Fertility Testing Kits - Fecal Occult Testing Kits - Food Pathogens Testing Kits - Others Prescription Mode - Over-the-counter (OTC) Testing Kits - Prescription-based Testing Kits End User - Professional Monitoring Kits - Patients Self-Monitoring Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Trends 6 Point-Of-Care Diagnostics Market, By Product 7 Point-Of-Care Diagnostics Market, By Prescription Mode 8 Point-Of-Care Diagnostics Market, By End User 9 Point-Of-Care Diagnostics Market, By Geography 10 Competitive Landscape 11 Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/fv...ointofcare
City of Chicago sues over painkiller marketing
By CARLA K. JOHNSON - AP - Tue Jun 03, 6:35PM CDT
CHICAGO (AP) — The city of Chicago is seeking damages in a lawsuit accusing five drugmakers of deceptively marketing a class of prescription painkiller that can be highly addictive.
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Final Glance: Pharmaceuticals companies
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 03, 12:31PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Jun 03, 12:31PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Medical Devices companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Will China's Price Gouging Accusations Have Any Impact on Johnson & Johnson and Other Eye Care Compa
Rich Duprey, The Motley Fool - Motley Fool - Tue Jun 03, 9:26AM CDT
Source: Wikimedia Commons Yet another industry has run afoul of China's antitrust laws, this time seven companies in eye care that were accused of fixing prices. According to the National Development and Reform Commission, the eye care companies...
Keen Strategy Partners with Effie Worldwide to Share Best Practices on Marketing Effectiveness from the World's Best Marketers
PR Newswire - Tue Jun 03, 5:24AM CDT
Raleigh-based Keen Strategy is partnering with Effie Worldwide to provide strategies on marketing effectiveness from a selection of the most effective marketers in North America.
Jim Cramer's Top Stock Picks: MWV MHR JNJ ADS
at The Street - Tue Jun 03, 5:00AM CDT
Cramer has some advice for Johnson & Johnson and thinks Alliance Data Systems is reviving retail.
Jim Cramer's 'Mad Money' Recap: Individual Stocks Rule
at The Street - Mon Jun 02, 7:16PM CDT
Cramer sounds off against the professional money managers who trade the market like it's merely a basket of commodities.
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
7 Stocks That Will Lift the Dow Jones Industrial Average to New High
at The Street - Mon Jun 02, 11:33AM CDT
Du Pont, Disney, Intel, Johnson & Johnson, Microsoft, Travelers and Exxon Mobil are likely to lift the Dow Jones Industrial Average to a new all-time high in June.
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 11:10AM CDT
Pharmacyclics (PCYC) announced positive late stage data on Imbruvica.
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $102.17
Comtex SmarTrend(R) - Mon Jun 02, 10:42AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.18 today and have reached the first resistance level of $101.82. Analysts will be watching for a cross of the next upside pivot targets of $102.17 and $103.16.
Cosmetic Product Companies Look to Expand Operations - Company Enters Agreement with Major Distributor for Sale of Beauty & Cosmetic Products in North America
PR Newswire - Mon Jun 02, 7:30AM CDT
Consumer goods companies specializing in cosmetics take steps to increase production and value with partnerships and other developments: Verde Media Group Inc. (OTC: VMGI), Elizabeth Arden, Inc. (NASDAQ: RDEN), Avon Products Inc. (NYSE: AVP), The Procter & Gamble Company (NYSE: PG), Johnson & Johnson (NYSE: JNJ) and Colgate-Palmolive Co. (NYSE: CL)
